The study investigated the effects of semaglutide on patients with heart failure and obesity.1 The results indicated that semaglutide had a positive impact on these patients, showing improvements in various health metrics. The research also made references to the HF-ACTION trial, which focused on exercise training outcomes for heart failure patients. The increase in the 6-minute walk distance observed with semaglutide was even more significant than the results from the HF-ACTION trial.
1
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., ... & Petrie, M. C. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine.
Share this post